This article will be expanded with more detailed information shortly.
This article will be expanded with more detailed information shortly.
This article will be expanded with more detailed information shortly.
ASML, the Dutch chipmaking giant, is investing €1.3 billion (about $1.5 billion) in French startup Mistral AI, marking Europe’s largest effort to rival U.S. dominance in artificial intelligence. This investment values Mistral at €10 billion, making it Europe’s most valuable AI startup. Founded in 2023 by former DeepMind and Meta researchers, Mistral aims to challenge U.S. companies like OpenAI and Google. ASML’s investment is strategic, as it seeks to integrate AI into its semiconductor manufacturing processes while reducing reliance on American and Chinese models. The collaboration could enhance innovation and strengthen Europe’s position in the AI landscape.
Iran has launched its first national open-source artificial intelligence platform, a significant step in enhancing its tech landscape. Unveiled in Tehran with support from the Vice Presidency for Science and Technology, the initiative involves esteemed university professors and specialists. Director Hosseini Asadi highlighted challenges in Iran’s AI sector, including lack of investment and a centralized platform. The project engages around 100 personnel and aims to deliver a stable version within a year. The platform’s potential spans healthcare, education, industry, and finance, positioning Iran as a key player in the global tech arena and fostering collaboration for innovation and growth.
Chinese scientists have developed a prototype superconducting quantum computer, Zuchongzhi-3, that reportedly outperforms the world’s most powerful supercomputers by a staggering 15 orders of magnitude. Operating at speeds 1 quadrillion times faster than the fastest classical supercomputer, this advancement marks a significant milestone in quantum technology, as detailed in a study published in Physical Review Letters. The research team claims that Zuchongzhi-3 successfully executed a larger-scale random circuit sampling task, previously unmatched by Google’s Sycamore processor. This breakthrough could revolutionize fields such as drug discovery, artificial intelligence, and material science, paving the way for new technological advancements.
Hosna Salimi, an Iranian PhD student in Indian Studies at the University of Tehran, has been awarded “Young Researcher of the Year” at the 2025 BRICS and SCO Young Leaders Award ceremony in Kazan, Russia. Competing against over 400 participants from 13 countries, Salimi’s recognition underscores her significant contributions to research relevant to contemporary issues in BRICS and SCO nations. Nominated by the Asian Mayors Forum, her achievement reflects the university’s commitment to fostering global talent. This accolade highlights the importance of young leaders in addressing global challenges and serves as an inspiration for aspiring researchers and leaders.
Microsoft employees are expressing serious concerns about the company’s email censorship practices, particularly regarding emails containing terms like “Palestine,” “Gaza,” and “genocide.” Reports emerged that these emails are being blocked or delayed, even in HR contexts, igniting debate about corporate policies versus social justice. Internal frustrations are evident as employees question the selective filtering, noting that terms like “Israel” are allowed. Despite Microsoft’s claims of no censorship, employees report significant delays, raising alarm over potential manual reviews. Protests against Microsoft’s ties to the Israeli military have intensified, highlighting ethical concerns surrounding the company’s operations and the impact of its technology in conflict zones.
A pioneering Iranian company has developed Tilmanoscept, an innovative nanodrug that promises to transform cancer detection in Iran. This advanced radiopharmaceutical enhances diagnostic accuracy while significantly lowering costs, making it more accessible for patients. Designed for injection alongside imaging scans, Tilmanoscept allows precise identification of cancerous lymph nodes and can scan the entire lymphatic system, benefiting around 90% of cancer patients. With local production ending a US monopoly, the drug reduces lymphatic mapping costs to one-tenth of the global price. As it moves into clinical trials, Tilmanoscept represents a significant advancement in cancer care and positions Iran as a leader in medical technology.